G
Gary L. Larsen
Researcher at Anschutz Medical Campus
Publications - 12
Citations - 1496
Gary L. Larsen is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Asthma & Montelukast. The author has an hindex of 8, co-authored 12 publications receiving 1445 citations. Previous affiliations of Gary L. Larsen include Jewish Hospital.
Papers
More filters
Journal ArticleDOI
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
Stanley J. Szefler,Brenda R. Phillips,Fernando D. Martinez,Vernon M. Chinchilli,Robert F. Lemanske,Robert C. Strunk,Robert S. Zeiger,Robert S. Zeiger,Gary L. Larsen,Joseph D. Spahn,Leonard B. Bacharier,Gordon R. Bloomberg,Theresa W. Guilbert,Gregory P. Heldt,Wayne J. Morgan,Mark H. Moss,Christine A. Sorkness,Lynn M. Taussig +17 more
TL;DR: Whether responses to ICSs and LTRAs are concordant for individuals or whether asthmatic patients who do not respond to one medication respond to the other is investigated.
Journal ArticleDOI
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial
Christine A. Sorkness,Robert F. Lemanske,David T. Mauger,Susan J. Boehmer,Vernon M. Chinchilli,Fernando D. Martinez,Robert C. Strunk,Stanley J. Szefler,Robert S. Zeiger,Robert S. Zeiger,Leonard B. Bacharier,Gordon R. Bloomberg,Ronina A. Covar,Theresa W. Guilbert,Gregory P. Heldt,Gary L. Larsen,Michael Mellon,Wayne J. Morgan,Mark H. Moss,Joseph D. Spahn,Lynn M. Taussig +20 more
TL;DR: The PACT study findings favor fluticasone monotherapy in treating children with mild-moderate persistent asthma with FEV(1) >or= 80% predicted, confirming current guideline recommendations.
Journal ArticleDOI
Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma
Robert S. Zeiger,Stanley J. Szefler,Brenda R. Phillips,Michael Schatz,Fernando D. Martinez,Vernon M. Chinchilli,Robert F. Lemanske,Robert C. Strunk,Gary L. Larsen,Joseph D. Spahn,Leonard B. Bacharier,Gordon R. Bloomberg,Theresa W. Guilbert,Gregory P. Heldt,Wayne J. Morgan,Mark H. Moss,Christine A. Sorkness,Lynn M. Taussig +17 more
TL;DR: The more favorable clinical, pulmonary, and inflammatory responses to an ICS than to an LTRA provide pediatric-based group evidence to support ICSs as the preferred first-line therapy for mild-to-moderate persistent asthma in children.
Journal ArticleDOI
Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma
TL;DR: IOS bronchodilator responses are remarkably abnormal in 4-year-old children, who are most likely to have persistent asthma, and might be a helpful objective outcome measure of early interventions.
Journal ArticleDOI
Pulmonary microvascular alterations and injury induced by complement fragments: synergistic effect of complement activation, neutrophil sequestration, and prostaglandins.
Peter M. Henson,Peter M. Henson,Gary L. Larsen,Gary L. Larsen,Robert O. Webster,Robert O. Webster,Brenda C. Mitchell,Brenda C. Mitchell,Alan J. Goins,Alan J. Goins,Jan E. Henson,Jan E. Henson +11 more
TL;DR: Fragments of C5 that are generated at, or administered to, extravascular sites in the pulmonary parenchyma induced neutrophil infiltration, edema, tissue damage, and a complete inflammatory response, while the combination of short episode of hypoxemia with the intravascular C5 activation led significant increases in pulmonary vascular permeability, mild endothelial alterations, and emigration of neutrophils.